Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Glandular Stomach | Positive | Equivocal Evidence | ADENOMA 0/49 1/50 0/50; ADENOCARCINOMA 0/49 1/501/50; SARCOMA 0/49 0/50 1/50 | May Have Been Related |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50 | Neoplastic Lesions |
| Yes | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Rats | F344/N | Male | Dosed-Water | Glandular Stomach | Clear Evidence | Clear Evidence | Adenoma 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Forestomach | Positive | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/49 1/50 0/50; FIBROSARCOMA 0/49 1/50 0/50; SARCOMA 0/49 0/50 1/50 | May Have Been Related |
| Yes | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Glandular Stomach | Positive | Equivocal Evidence | ADENOMA 0/49 1/50 0/50; ADENOCARCINOMA 0/49 1/501/50; SARCOMA 0/49 0/50 1/50 | May Have Been Related |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Equivocal Evidence | LYMPHOMA 10/50 16/50 19/50 | May Have Been Related |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | ADENOMA 0/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | NEOPLASTIC NODULE 1/49 15/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50 | May Have Been Related |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 5/50 5/50 15/50 13/50 6/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50 | Neoplastic Lesions |
| No | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Mice | B6C3F1/N | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | Squamous cell papilloma 1/50 0/50 5/50 14/50 | Neoplastic Lesions |
| No | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Mice | B6C3F1/N | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | Squamous cell papilloma or carcinoma 0/50 1/50 0/50 5/50 | Neoplastic Lesions |
| Yes | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Rats | F344/N | Male | Dosed-Water | Glandular Stomach | Clear Evidence | Clear Evidence | Adenoma 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Mice | B6C3F1/N | Male | Dosed-Water | Liver | Clear Evidence | Equivocal Evidence | Hepatoblastoma 1/50 7/50 3/50 2/50 adenoma, carcinoma or hepatoblastoma 37/50 46/50 43/50 42/50 | May Have Been Related |
| No | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Squamous cell papilloma or carcinoma 0/50 0/50 2/50 5/50 | Neoplastic Lesions |
| No | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Some Evidence | Some Evidence | Squamous cell papilloma 1/50 0/50 4/50 0/50 | Neoplastic Lesions |
| No | TR-544 | 3252-43-5 | Water disinfection byproducts (Dibromoacetonitrile) | Rats | F344/N | Female | Dosed-Water | Skin | Some Evidence | Equivocal Evidence | Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 0/50 0/50 3/50 4/50 | May Have Been Related |